Literature DB >> 12351413

Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions.

Roelandt F J Schop1, W Michael Kuehl, Scott A Van Wier, Gregory J Ahmann, Tammy Price-Troska, Richard J Bailey, Syed M Jalal, Ying Qi, Robert A Kyle, Philip R Greipp, Rafael Fonseca.   

Abstract

Lymphoplasmacytic lymphoma (LPL) is characterized by t(9;14)(p13;q32) in 50% of patients who lack paraproteinemia. Waldenström macroglobulinemia (WM), which has an immunoglobulin M (IgM) paraproteinemia, is classified as an LPL. Rare reports have suggested that WM sometimes is associated with 14q23 translocations, deletions of 6q, and t(11;18)(q21;q21). We tested for these abnormalities in the clonal cells of WM patients. We selected patients with clinicopathologic diagnosis of WM (all had IgM levels greater than 1.5 g/dL). Southern blot assay was used to detect legitimate and illegitimate IgH switch rearrangements. In addition to conventional cytogenetic (CC) and multicolor metaphase fluorescence in situ hybridization (M-FISH) analyses, we used interphase FISH to screen for t(9;14)(p13;q32) and other IgH translocations, t(11;18)(q21;q21), and 6q21 deletions. Genomic stability was also assessed using chromosome enumeration probes for chromosomes 7, 9, 11, 12, 15, and 17 in 15 patients. There was no evidence of either legitimate or illegitimate IgH rearrangements by Southern blot assay (n = 12). CC (n = 37), M-FISH (n = 5), and interphase FISH (n = 42) failed to identify IgH or t(11;18) translocations. Although tumor cells from most patients were diploid for the chromosomes studied, deletions of 6q21 were observed in 42% of patients. In contrast to LPL tumors that are not associated with paraproteinemia and that have frequent t(9;14)(p13;q32) translocations, IgH translocations are not found in WM, a form of LPL tumor distinguished by IgM paraproteinemia. However, WM tumor cells, which appear to be diploid or near diploid, often have deletions of 6q21.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12351413     DOI: 10.1182/blood.V100.8.2996

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

Review 1.  Molecular pathogenesis of Waldenstrom's macroglobulinemia.

Authors:  Esteban Braggio; Casey Philipsborn; Anne Novak; Lucy Hodge; Stephen Ansell; Rafael Fonseca
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

2.  Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families.

Authors:  Mary L McMaster; Lynn R Goldin; Yan Bai; Monica Ter-Minassian; Stefan Boehringer; Therese R Giambarresi; Linda G Vasquez; Margaret A Tucker
Journal:  Am J Hum Genet       Date:  2006-08-31       Impact factor: 11.025

3.  microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.

Authors:  Aldo M Roccaro; Antonio Sacco; Changzhong Chen; Judith Runnels; Xavier Leleu; Feda Azab; Abdel Kareem Azab; Xiaoying Jia; Hai T Ngo; Molly R Melhem; Nicholas Burwick; Lyuba Varticovski; Carl D Novina; Barrett J Rollins; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

4.  Fatal cerebral hemorrhage in a patient with CD19-positive IgM-producing aggressive plasma cell myeloma, hyperviscosity syndrome and cryoglobulinemia.

Authors:  Adnan Alatoom; Rania Elsabrouty; Jason Willis; Christie Boils; Ravindra Sarode; Ibrahim Hashim; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2009-02-09

Review 5.  The bone marrow microenvironment in Waldenström macroglobulinemia.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-03-13

Review 6.  Molecular diagnosis in lymphoma.

Authors:  Adam Bagg
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

7.  Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.

Authors:  Florence Nguyen-Khac; Jerome Lambert; Elise Chapiro; Aurore Grelier; Sarah Mould; Carole Barin; Agnes Daudignon; Nathalie Gachard; Stéphanie Struski; Catherine Henry; Dominique Penther; Hossein Mossafa; Joris Andrieux; Virginie Eclache; Chrystèle Bilhou-Nabera; Isabelle Luquet; Christine Terre; Laurence Baranger; Francine Mugneret; Jean Chiesa; Marie-Joelle Mozziconacci; Evelyne Callet-Bauchu; Lauren Veronese; Hélène Blons; Roger Owen; Julie Lejeune; Sylvie Chevret; Hélène Merle-Beral; Véronique Leblondon
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

8.  Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden.

Authors:  Ola Landgren; Sigurdur Y Kristinsson; Lynn R Goldin; Neil E Caporaso; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Magnus Bjorkholm; Ingemar Turesson
Journal:  Blood       Date:  2009-01-30       Impact factor: 22.113

Review 9.  MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.

Authors:  O Landgren; N Tageja
Journal:  Leukemia       Date:  2014-02-27       Impact factor: 11.528

Review 10.  Novel treatment options for Waldenström macroglobulinemia.

Authors:  Houry Leblebjian; Amit Agarwal; Irene Ghobrial
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.